• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从肝脏到激素:肝硬化的内分泌后果。

From liver to hormones: The endocrine consequences of cirrhosis.

机构信息

Non-communicable Diseases, Endocrinology Research Line, Hospital de Apoyo Chepén, Chepén 13871, Peru.

Department of Endocrinology, Hospital Víctor Lazarte Echegaray, Trujillo 13006, Peru.

出版信息

World J Gastroenterol. 2024 Mar 7;30(9):1073-1095. doi: 10.3748/wjg.v30.i9.1073.

DOI:10.3748/wjg.v30.i9.1073
PMID:38577191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10989500/
Abstract

Hepatocrinology explores the intricate relationship between liver function and the endocrine system. Chronic liver diseases such as liver cirrhosis can cause endocrine disorders due to toxin accumulation and protein synthesis disruption. Despite its importance, assessing endocrine issues in cirrhotic patients is frequently neglected. This article provides a comprehensive review of the epidemiology, pathophysiology, diagnosis, and treatment of endocrine disturbances in liver cirrhosis. The review was conducted using the PubMed/Medline, EMBASE, and Scielo databases, encompassing 172 articles. Liver cirrhosis is associated with endocrine disturbances, including diabetes, hypoglycemia, sarcopenia, thyroid dysfunction, hypogonadotropic hypogonadism, bone disease, adrenal insufficiency, growth hormone dysfunction, and secondary hyperaldosteronism. The optimal tools for diagnosing diabetes and detecting hypoglycemia are the oral glucose tolerance test and continuous glucose monitoring system, respectively. Sarcopenia can be assessed through imaging and functional tests, while other endocrine disorders are evaluated using hormonal assays and imaging studies. Treatment options include metformin, glucagon-like peptide-1 analogs, sodium-glucose co-transporter-2 inhibitors, and insulin, which are effective and safe for diabetes control. Established standards are followed for managing hypoglycemia, and hormone replacement therapy is often necessary for other endocrine dysfunctions. Liver transplantation can address some of these problems.

摘要

肝胆病学探讨了肝功能与内分泌系统之间的复杂关系。慢性肝脏疾病(如肝硬化)可能由于毒素积累和蛋白质合成障碍而导致内分泌紊乱。尽管其重要性,评估肝硬化患者的内分泌问题常常被忽视。本文全面回顾了肝硬化内分泌紊乱的流行病学、病理生理学、诊断和治疗。综述使用了 PubMed/Medline、EMBASE 和 Scielo 数据库,共纳入了 172 篇文章。肝硬化与内分泌紊乱相关,包括糖尿病、低血糖、肌肉减少症、甲状腺功能障碍、促性腺激素释放激素不足、性腺功能减退、骨疾病、肾上腺皮质功能减退、生长激素功能障碍和继发性醛固酮增多症。诊断糖尿病的最佳工具是口服葡萄糖耐量试验,检测低血糖的最佳工具是连续血糖监测系统。可以通过影像学和功能测试评估肌肉减少症,其他内分泌紊乱则通过激素测定和影像学研究进行评估。治疗选择包括二甲双胍、胰高血糖素样肽-1 类似物、钠-葡萄糖共转运蛋白-2 抑制剂和胰岛素,这些药物对糖尿病控制既有效又安全。对于低血糖,遵循既定标准进行治疗,对于其他内分泌功能障碍,通常需要进行激素替代治疗。肝移植可以解决其中一些问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4294/10989500/4d7dd880e17d/WJG-30-1073-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4294/10989500/d40bbed12e61/WJG-30-1073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4294/10989500/4d7dd880e17d/WJG-30-1073-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4294/10989500/d40bbed12e61/WJG-30-1073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4294/10989500/4d7dd880e17d/WJG-30-1073-g002.jpg

相似文献

1
From liver to hormones: The endocrine consequences of cirrhosis.从肝脏到激素:肝硬化的内分泌后果。
World J Gastroenterol. 2024 Mar 7;30(9):1073-1095. doi: 10.3748/wjg.v30.i9.1073.
2
Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions.综述文章:肝硬化中的肌肉减少症——病因、影响及潜在治疗干预措施
Aliment Pharmacol Ther. 2016 Apr;43(7):765-77. doi: 10.1111/apt.13549. Epub 2016 Feb 5.
3
Clinical relevance of sarcopenia in patients with cirrhosis.肝硬化患者中肌肉减少症的临床相关性。
World J Gastroenterol. 2014 Jul 7;20(25):8061-71. doi: 10.3748/wjg.v20.i25.8061.
4
Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge.肝脏疾病中肌肉减少症的分子机制与治疗:现有知识综述。
Int J Mol Sci. 2021 Jan 31;22(3):1425. doi: 10.3390/ijms22031425.
5
Prevalence of diabetes mellitus and impaired glucose tolerance in patients with decompensated cirrhosis being evaluated for liver transplantation: the utility of oral glucose tolerance test.正在接受肝移植评估的失代偿期肝硬化患者中糖尿病和糖耐量受损的患病率:口服葡萄糖耐量试验的效用
Arq Gastroenterol. 2010 Jan-Mar;47(1):22-7. doi: 10.1590/s0004-28032010000100005.
6
Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation.胰岛素敏感性和分泌降低在肝源性糖尿病发病机制中的作用:肝移植的影响。
Hepatology. 2000 Mar;31(3):694-703. doi: 10.1002/hep.510310320.
7
Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential.代偿期肝硬化患者的2型糖尿病管理:证据不足,潜力巨大。
Diabetes Metab Syndr. 2024 Jan;18(1):102935. doi: 10.1016/j.dsx.2023.102935. Epub 2023 Dec 28.
8
Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments.肝硬化和胰岛素抵抗:当前的认识、病理生理机制、并发症和潜在治疗方法。
Clin Sci (Lond). 2020 Aug 28;134(16):2117-2135. doi: 10.1042/CS20200022.
9
Sarcopenia and Frailty in Cirrhosis: Assessment and Management.肝硬化相关的肌肉减少症和衰弱:评估和管理。
Med Clin North Am. 2023 May;107(3):589-604. doi: 10.1016/j.mcna.2022.12.007. Epub 2023 Feb 20.
10
[Pancreatic polypeptide response to oral glucose load in patients with liver cirrhosis--interrelationship between PP and other pancreatic endocrine hormones].[肝硬化患者口服葡萄糖负荷后胰多肽的反应——胰多肽与其他胰腺内分泌激素之间的相互关系]
Nihon Naibunpi Gakkai Zasshi. 1988 Mar 20;64(3):155-70. doi: 10.1507/endocrine1927.64.3_155.

引用本文的文献

1
Interplay between endocrine disorders and liver dysfunction: Mechanisms of damage and therapeutic approaches.内分泌紊乱与肝功能障碍之间的相互作用:损伤机制与治疗方法
World J Gastroenterol. 2025 Aug 28;31(32):108827. doi: 10.3748/wjg.v31.i32.108827.
2
Correlation between gynecomastia and endocrine regulation in patients with metabolic dysfunction-associated fatty liver disease: A cross-sectional study.代谢功能障碍相关脂肪性肝病患者男性乳腺增生与内分泌调节的相关性:一项横断面研究。
World J Hepatol. 2025 Jun 27;17(6):108096. doi: 10.4254/wjh.v17.i6.108096.
3
Increased Risk of Early-Onset Endometrial Cancer in Women Aged 20-39 Years with Non-Alcoholic Fatty Liver Disease: A Nationwide Cohort Study.

本文引用的文献

1
Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH).翻译发现——代谢功能障碍相关脂肪性肝炎(MASH)中的纤维化
Sci Transl Med. 2023 Oct 4;15(716):eadi0759. doi: 10.1126/scitranslmed.adi0759.
2
Refractory Hypothyroidism: Unraveling the Complexities of Diagnosis and Management.难治性甲状腺功能减退症:解读诊断与管理的复杂性
Endocr Pract. 2023 Dec;29(12):1007-1016. doi: 10.1016/j.eprac.2023.09.003. Epub 2023 Sep 13.
3
Endocrinology for the hepatologist.肝病学家的内分泌学
20至39岁非酒精性脂肪性肝病女性患早发性子宫内膜癌的风险增加:一项全国性队列研究
Cancers (Basel). 2025 Apr 14;17(8):1322. doi: 10.3390/cancers17081322.
4
Embryonic lethal abnormal vision like 1-stabilized histone deacetylase 6 promotes hepatic stellate cell activation to accelerate liver fibrosis progression through ribosomal protein S5 downregulation.胚胎致死性异常视觉样蛋白1稳定的组蛋白去乙酰化酶6通过下调核糖体蛋白S5促进肝星状细胞活化,加速肝纤维化进程。
Cytojournal. 2025 Mar 6;22:30. doi: 10.25259/Cytojournal_221_2024. eCollection 2025.
5
An atypical presentation of autoimmune hepatitis with delayed menarche in a Nigerian adolescent: a case report.一名尼日利亚青少年自身免疫性肝炎伴初潮延迟的非典型表现:病例报告
J Med Case Rep. 2025 Jan 24;19(1):34. doi: 10.1186/s13256-025-05051-2.
6
Gut‑liver axis in liver disease: From basic science to clinical treatment (Review).肠道-肝脏轴在肝脏疾病中的作用:从基础科学到临床治疗(综述)。
Mol Med Rep. 2025 Jan;31(1). doi: 10.3892/mmr.2024.13375. Epub 2024 Oct 25.
7
Hepatic immune regulation and sex disparities.肝脏免疫调节与性别差异。
Nat Rev Gastroenterol Hepatol. 2024 Dec;21(12):869-884. doi: 10.1038/s41575-024-00974-5. Epub 2024 Sep 5.
Clin Liver Dis (Hoboken). 2023 May 16;22(1):1-6. doi: 10.1097/CLD.0000000000000037. eCollection 2023 Jul.
4
Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality.他汀类药物的使用与肝病、肝细胞癌和与肝脏相关的死亡率的关系。
JAMA Netw Open. 2023 Jun 1;6(6):e2320222. doi: 10.1001/jamanetworkopen.2023.20222.
5
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).2023ESH 动脉高血压管理指南 欧洲高血压学会动脉高血压管理工作组:得到国际高血压学会 (ISH) 和欧洲肾脏协会 (ERA) 的认可。
J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26.
6
Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.胰高血糖素样肽-1 受体激动剂在肝硬化合并 2 型糖尿病患者中的应用。
Clin Gastroenterol Hepatol. 2024 Jun;22(6):1255-1264.e18. doi: 10.1016/j.cgh.2023.06.004. Epub 2023 Jun 16.
7
Global burden of liver disease: 2023 update.全球肝病负担:2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
8
Global epidemiology of cirrhosis - aetiology, trends and predictions.全球肝硬化的流行病学:病因、趋势和预测。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28.
9
Hypoglycemia on admission in patients with acute on chronic liver failure: a retrospective cohort analyzing the current situation, risk factors, and associations with prognosis.慢性肝功能衰竭急性发作患者入院时的低血糖症:一项回顾性队列研究,分析现状、危险因素及与预后的关联
Ann Palliat Med. 2023 Jan;12(1):163-170. doi: 10.21037/apm-22-1422.
10
MAFLD: a multisystem disease.代谢相关脂肪性肝病:一种多系统疾病。
Ther Adv Endocrinol Metab. 2023 Jan 28;14:20420188221145549. doi: 10.1177/20420188221145549. eCollection 2023.